Calibrant, Yale to Collaborate on Ovarian, Breast Cancer Drug ID Study | GenomeWeb
NEW YORK (GenomeWeb News) – Calibrant Biosystems today said that it will collaborate with researchers at the Yale University School of Medicine to identify ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.